- Home
- STSS vs IMA Comparison
STSS vs IMA Comparison
Compare STSS & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$2.27
N/A
Current Price
$6.19
Company Overview
Basic Information| Metric | STSS | IMA |
|---|---|---|
| Founded | 2017 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.3M | 92.2M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | STSS | IMA |
|---|---|---|
| Price | $2.27 | $6.19 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | ★ 258.3K | 64.1K |
| Earning Date | 11-17-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $306,344.00 | ★ $800,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.01 | $6.11 |
| 52 Week High | $690.01 | $18.00 |
Technical Indicators
Market Signals| Indicator | STSS | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 34.88 | N/A |
| Support Level | $2.01 | N/A |
| Resistance Level | $2.90 | N/A |
| Average True Range (ATR) | 0.28 | 0.00 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 18.44 | 0.00 |
Price Performance
Historical Comparison STSS
IMA
About STSS Sharps Technology Inc.
Sharps Technology Inc is a medical device company. It offers syringes and other safety products. Sharps provensa, Securgard, and Sologard are ultra-low waste smart safety syringes designed to eliminate potentially infectious and accidental needlestick injuries.
About IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company that develops differentiated therapies for immunological and inflammatory (I&I) diseases. The company is focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis.